BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15001338)

  • 1. Ximelagatran or warfarin in atrial fibrillation?
    Epstein EF
    Lancet; 2004 Feb; 363(9410):736; author reply 736. PubMed ID: 15001338
    [No Abstract]   [Full Text] [Related]  

  • 2. Ximelagatran or warfarin in atrial fibrillation?
    Stöllberger C; Finsterer J
    Lancet; 2004 Feb; 363(9410):734-5; author reply 736. PubMed ID: 15001336
    [No Abstract]   [Full Text] [Related]  

  • 3. Ximelagatran or warfarin in atrial fibrillation?
    Eikelboom J; Hankey G
    Lancet; 2004 Feb; 363(9410):734; author reply 734, 736. PubMed ID: 15001334
    [No Abstract]   [Full Text] [Related]  

  • 4. Ximelagatran or warfarin in atrial fibrillation?
    MacAllister R; Hingorani AD; Casas JP
    Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
    [No Abstract]   [Full Text] [Related]  

  • 5. Can we pull the plug on warfarin in atrial fibrillation?
    Verheugt FW
    Lancet; 2003 Nov; 362(9397):1686-7. PubMed ID: 14643112
    [No Abstract]   [Full Text] [Related]  

  • 6. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ximelagatran for stroke prevention.
    Perret-Guillaume C; Wahl D
    JAMA; 2005 Jun; 293(23):2860-1; author reply 2861. PubMed ID: 15956626
    [No Abstract]   [Full Text] [Related]  

  • 8. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
    Kulbertus H
    Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
    Berry C; Norrie J; McMurray JJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
    Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
    JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
    Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Cavuşoğlu Y
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
    [No Abstract]   [Full Text] [Related]  

  • 15. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
    Olsson SB;
    Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran--promises and concerns.
    Gurewich V
    JAMA; 2005 Feb; 293(6):736-9. PubMed ID: 15701916
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Tandoğan I
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):216; author reply 218-9. PubMed ID: 17513230
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Kiraç FS
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):214-5; author reply 218-9. PubMed ID: 17513229
    [No Abstract]   [Full Text] [Related]  

  • 20. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.